drugset / Trial / NCT04682964
Bacteriophage Therapy in Tonsillitis
Phase 3
Active not recruiting
128 enrolled
Tashkent State Medical University (Tashkent Pediatric Medical Institute), Uzbekistan
NaSingle-groupOpen-labelSupportive care
Summary
The patients received bacteriophage therapy with a liquid piobacteriophage complex (liquid pyobacteriophage complex - PCL). PСL was administered via nebulizer inhalation to irrigate the tonsil mucosa. A total of 5 ml of PCL was inhaled for 10 minutes every 5 days. The drug causes the lysis of certain bacteria, including staphylococcus, enterococcus, streptococcus, enteropathogenic E. coli, Proteus vulgaris, Proteus mirabilis, Pseudomonas aeruginosa, Klebsiella pneumoniae and Klebsiella oxytoca. The choice of this drug was based on bacteriological studies.
Timeline
- Start
- 2020-10-02
- Primary completion
- 2025-12-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | liquid piobacteriophage complex | Unknown | 5 ml | Inhaled |